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In search for specific early ultrasound signs that could indicate an increased risk of 
hereditary or acquired disorders of the fetus, scientific researches confirm the value of 
exceptional ultrasound findings of nuchal translucencey (NT). 
The aim of the study was to determine the predictive value of the diameter of fetal 
NT in the detection of chromosomopathy.  
The investigation included 317 pregnant women with monofetal pregnancies, 
gestational age 11-14 weeks. The control group consisted of pregnant women in whom, 
after amniocentesis, a regular result of fetal karyotype was obtained. The limits of 
physiological and pathological findings of the NT value were not determined; instead, we 
used the diameters of NT that were obtained in pregnant women with pathological score 
of amniocentesis as potentially pathological values.  
Mean value of NT in the control group was 1.92±0.39mm, and in the group with 
pathological findings of fetal karyotype it was 2.49±0.37mm, which is a statistically 
significant difference (p<0.05). Mean value of the rump-crown length in the control 
group was 64.83±8.23mm, and the group with pathological karyotype 60.12±8.48mm; 
gestational age in the control group was 7.10±87.40 days, and in the pathological one 
85.69±3.98 days, which speaks of homogeneity of the investigated sample 
(p>0.05).The probability that a patient with negative NT findings be healthy is 0.97. NT 
sensitivity as a marker for chromosomopathy was 0.97. The rate of false positive 
findings was 0.027. Specificity of NT as a marker for chromosomopathy was 0.97. The 
probability that a patient with positive findings NT really be ill was 0.66. 
Valid findings of NT can be considered safe ultrasonographic markers in the 
assessment of absence of chromosomopathy. Pathological finding, given the low positive 
predictive value of NT, must be amended by other prenatal tests before a pregnant 
woman is advised on prenatal invasive diagnostics. Acta Medica Medianae 2011; 
50(1):11-16.  
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  Introduction 
 
As part of antenatal care - monitoring 
growth and development of the unborn child, in 
most European countries three standard ultrasound 
examinations are recommended: between 9
th and 
12
th week, then 19
th and 22
nd as well as 29
th 
week and 32
nd week (1). In any irregularity or 
the occurrence of complications in pregnancy, 
ultrasound examination provides additional 
security for pregnant woman as well as for a 
gynecologist who monitors the pregnancy. During 
searching for early specific ultrasound signs - 
markers that might indicate an increased risk of 
hereditary or acquired disorders - fetal chromo-
somopathy, scientific researches confirm the 
exceptional value of ultrasound finding of the 
nuchal translucency (nuchal translucency, NT) 
(2). Nuchal translucency indicates ultrasound 
finding of the fluid accumulation (lymph) between 
the skin and subcutaneous fascia in the neck area 
or neck and back of the embryo, which is 
detected by ultrasound examination between 11
th 
and 14
th w e e k  o f  p r e g n a n c y  t h a t  i s  w h e n  t h e  
crown-rump length (CRL) is between 45-84 mm 
(3). Nuchal skin fold thickness that is usually 
tolerated is less than 99
th  percentile for CRL. 
Numerous studies show a connection of this 
ultrasound marker finding (nuchal translucency ≥ 
3mm) with the specified chromosomal aberrations, 
especially with aneuploidy and Down syndrome. 
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The connection of this finding with Down 
syndrome is important to the extent that most 
authors, who study this phenomenon, classify 
ultrasound finding of nuchal fold in the screening 
procedures for Down syndrome. In the largest of 
all studies (King's group) in more than  96.000 
pregnancies  (22 perinatal centers, 306 gyne-
cologists), this ultrasound finding was detected in 
82% of fetuses with Down syndrome (incidence 
of false positives: 8.3%). Besides the association 
to chromosomal aberrations, the result from 
nuchal fold is also a marker for other genetic 
syndromes, in which process it is most frequently 
about cardiac anomalies. Fetal NT increases with 
CRL and therefore it is very important to take 
gestation age into account when determining 
whether the measured NT is increased or not (4). 
In a study involving 96.127 pregnancies, the 
mean value and 95
th percentile of NT at a CRL of 
45 mm were 1.2 and 2.1 mm, and with the CRL 
of 84 mm, 1.9 and 2.7 mm (5). With pregnancies 
with fetal NT below the 99
th  percentile (3.5 mm), 
the parents decision of whether the fetal 
karyotype is to be determined will depend on 
individual risk, which is derived from a 
combination of maternal age, ultrasound findings 
and free β-hCG and PAPP-A in maternal serum at 
11-13 +6 weeks (6).  
 
Study aim 
 
The aim was to determine the predictive 
value of the diameter of fetal nuchal translucency 
in detecting chromosomopathy. 
 
Respondents and study methods 
 
The study was carried out at the 
Gynecology and Obstetrics Clinic (GOC), in the 
Clinical Center Kragujevac on singleton intrauterine 
pregnancies in the first trimester of pregnancy 
during the period 2007-2009. During the 
research, we used a clinical-experimental study 
model. To every pregnant woman, who was 
planned for inclusion into the study, we explained 
in detail the plan and purpose of examination, 
and all respondents included in the study gave 
their voluntary written consent for testing after 
reading the information. The study included 317 
pregnant women with monofetal pregnancies that 
were observed by the Genetic Counseling 
Commission of GOC CC Kragujevac.  
Requirements for inclusion of pregnant 
woman in the study were related to following 
pregnancy parameters: 
1. Distance CRL (crown-rump length) has 
to be from 45 to 84 mm. 
2. Gestational age of pregnancy must be of 
11-13 +6 weeks. 
During the measurement of fetal NT, we 
used high-resolution ultrasound machine Aloka 
Pro Sound 3500 with the option "cine loop” for 
restoring the image, with calipers that provide 
measurement of one decimal. The screen image 
on which the NT is measured enclosed only the 
head and the upper part of the thorax. 
Magnification was at maximum, so that each 
slight caliper movement changes the measure by 
only 0.1 mm. Nuchal translucency was measured 
with the fetus in the neutral position. We 
measured a maximum thickness of the 
subcutaneous illumination between the skin and 
soft tissue in the cervical part of the spine. 
Calipers were placed on the lines that define the 
fold, so they were hardly visible on the white 
border line of the fold behind the neck. During 
the examination, we made a couple of 
measurements, and took into account the 
greatest thickness. In case the umbilical cord was 
around the fetal neck (in about 8% of cases) we 
measured NT thickness above and below the cord 
and used the average value of the two measures. 
All pregnant women underwent early amniocentesis, 
after which fetal karyotype was determined. For 
statistical processing, parametric and nonpara-
metric tests were used for the significance of 
difference - t test, χ2 test, Fisher's exact test and 
contingency tables in order to calculate the 
parameters of predictive statistics. 
 
Study results 
 
This  chapter  presents the results of  the 
study. 
 
Table 2. Outline of mean values and standard 
deviations of the ultrasonographic parameters in the 
total sample 
 
Parameters 
Pathological 
karyotype 
=16 
Control 
group =311 
P 
Nuchal 
translucency 
(mm)  
2.49±0.37 1.92±0.39  <0.05 
Crown-rump 
length (mm) 
60.12±8.48 64.83±8.23  p>0,05 
Gestational age 
(days) 
85.69±3.98 87.40±7.10  p>0.05 
 
The nuchal translucency diameter was 
significantly different in statistics of pregnant 
women groups (p <0.05). Crown-rump length 
and gestational age were not significantly 
different (p> 0.05). 
  After performed amniocentesis we divided 
the obtained karyotype results into two groups as 
follows: pregnant women with numerical aberrations 
(SP) and those with structural disorders on the 
chromosome level (LP). 
  By using contingency tables we have been 
determining the predictive value of nuchal trans-
lucency (NT) as a possible marker of invasive 
prenatal screening of pregnant women in 
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Table 1. Ultrasonographic markers outline in pregnant women group with pathological karyotype result after early 
amniocentesis 
 
Register protocol 
number -year 
Nuchal translucency 
in mm (NT) 
Crown-rump 
length in mm 
(CRL) 
Gestacional age in 
days (GA) 
 
Karyotype result after early 
amniocentesis 
 
3-2007 2.2  60 86  46,xy/47xyy 
11-2007  3.0  62  88  46,xx/46,xx; del 7t(7;17) 
47-2007 2.5  65  88  47,xy  +21 
151-2007 2.6  63  86  47xy+21 
74-2008 1.8  73  90  47,  xy+18 
76-2008 2.4  72  89 
Robertsonian translocation 45, 
xy,-14, -21 +t (14q;21q) 
158-2008 2.5  56  82  47,  xx+21 
99-2008 2.6  65  87 
Robertsonian translocation 
45,xx,-14,-21+t (14q21q) 
161-2008 2.7  48  81  47,  xx+21 
164-2008 2.0  50  81 
46,xy/46, y 
del(x)t(7;x)q35;q22) 
162-2008 1.9  48  78 46,xy/46,xy  (-4q3) 
167-2008 3.1  48  80  47,xy+21 
231-2009 2.8  61  89  47,xx+21 
267-2009 2.6  71  91  47,xx+21 
237-2009  2.4  56  87  46,xx/47,xx t (9;6)(q31;q14) 
271-2009 2.8  64  88  46,  xy/47,xy+13 
 
 
 
Graph 1. Value distribution of nuchal translucency (NT) 
in relation to the distance between crown-rump lengths 
(CRL) in the total sample 
 
 
 
Graph 3. Value distribution of nuchal translucency (NT 
pathological) with pathological karyotypes in relation to 
crown-rump length (CRL pathological) 
 
 
Graph 2. Value distribution of nuchal translucency (NT) 
in relation to gestational age of pregnancy (NG / days) 
in the total sample 
 
 
 
Graph 4. Value distribution of nuchal translucency (NT 
pathological) in pathological karyotypes in relation to 
gestational age of pregnancy (NG pathological) 
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Table 3. Contingency table 
 
Test result 
Disease 
present 
Disease 
absent 
Total 
Positive  SP -16  LP- 8  SP+LP -24 
Negative  LN -8  SN-285  LN+SN- 293 
Total  SP+LN- 24  LP+SN-293  N- 317 
 
Legend: 
SP-really positive;  
LP-false positive;  
LN-false negative;  
SN- really negative 
Positive predictive value SP/SP+LP = 0.66 
Negative predictive value SN/SN+LN=0.97 
Positive predictive value shows the number 
of people with positive test result that have the 
disease. 
Negative predictive value shows the 
number of people with negative test result that 
do not have the disease. 
The likelihood that a patient with positive 
N T  r e s u l t  w i l l  r e a l l y  b e  s i c k ,  t h a t  i s  t o  h a v e  a  
numerical aberration is 0.66. 
The likelihood that a patient with negative 
result of nuchal translucency (NT) will be healthy 
is 0.97.  
We determined the sensitivity of measurement 
of nuchal translucency (NT) as a marker for 
chromosomopathy according to the formula: SPP 
SP / SP + LN = 0.66. 
False-positive rate was determined by the 
following formula:  SLP=LP/LP+SN=0.027 
We were determining the specificity of 
measurement of nuchal translucency (NT) as a 
marker for chromosomopathy according to the 
formula: 
SSN=SN/SN+LP=0.97. 
 
Discussion 
 
Implementation of NT screening in routine 
clinical practice was a theme of several 
prospective intervention studies (7). In some 
studies, the positive screening group was defined 
by the limit value of fetal NT or by combined risk 
derived from maternal age and NT deviation from 
the normal median for CRL. The important results 
of these studies were: (1) NT was successfully 
measured in more than 99% of cases, (2) there 
was the inevitable variation in false positive rates 
and detection rates between different studies, 
because of differences in age of examined 
women, the distribution of the examined 
population and used limit value of NT or risk and 
(3) in the combined data of more than 200.000 
pregnancies, including more than 900 fetuses 
with trisomy 21; screening by NT identified more 
than 75% of fetuses with trisomy 21 and other 
major chromosomopathies with a false positive 
rate of 5%, and the detection rate was 60% for a 
false positive ratio of 1% (7). In the largest 
study, coordinated by the Fetal Medicine Foundation, 
306 appropriately trained operators examined 
100.311 singleton pregnancies at 22 centers in 
the United Kingdom (8). In all cases, CRL and NT 
were measured and the individual risks were 
calculated, based on maternal age, gestational 
age and fetal NT. Pregnancy outcomes were 
obtained in 96.127 cases, including 326 with 
trisomy 21 and 325 with other chromosomo-
pathies. The mean gestation at the time of 
screening was 12 weeks and the mean maternal 
age was 31 years. The estimated risk for trisomy 
21 was above 1 in 300 or more in 8% of normal 
pregnancies, in 82% of trisomy 21 pregnancies 
and 78% with other chromosomopathies. For 
positive screening rate of 5%, the detection rate 
was 77% (95% confidence interval 72-82%). The 
issue of fetal mortality has advantages over 
screening in the second trimester - earlier 
prenatal diagnosis and thus less traumatic 
termination of pregnancy for those couples who 
decide for this option. Potential lack of early 
screening is that it identifies those pregnancies 
with chromosomopathies that will be miscarried 
spontaneously. About 30% of all fetuses with 
trisomy 21 die between 12 weeks of gestation 
and delivery term. The issue of spontaneous 
intrauterine death with fetuses with chromosomo-
pathies is, of course, a potential criticism of all 
antenatal screening methods, including biochemical 
screening in the second trimester because fetal 
mortality is about 20% between 16 weeks and 
delivery term. From prenatal screening studies it 
is not possible to find out how many pregnancies 
with fetuses with trisomy 21 that were 
terminated would actually result in liveborn 
children; however, it is still possible to assess the 
impact of prenatal screening on the prevalence of 
trisomy 21 with liveborn children. This can be 
done by comparing the number of liveborn 
children with trisomy 21 to the number estimated 
on the basis of prevalence of trisomy 21 of 
liveborn children according to the maternal age 
and maternal age distribution of the examined 
population. In the screening study of the Fetal 
Medicine Foundation, by combination of maternal 
age and fetal NT, the risk limit value of 1 in 300 
had a false positive rate of 8% and a detection 
rate of 82% (8). It was estimated that prenatal 
screening would, after invasive diagnostics and 
selective termination of fetuses with trisomy 21, 
decrease the prevalence of potential liveborn 
children with trisomy 21 by 78-82%. The ability 
to obtain reliable measurement of NT thickness is 
dependent on adequate training, use of standard 
techniques and motivation of operators. The 
importance of all three components can be seen 
on the example of difference in results between 
intervention and observation studies, during 
which the operators measured the NT thickness, 
but did not act in case of increased thickness (7). 
In intervention studies, in over 99% of the cases, 
the NT measurement was successful, unlike 
observation studies, where NT was successfully 
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intervention studies, NT thickness was increased 
in 76% of trisomy 21 and 4.2% of chromo-
somally normal fetuses, compared with 38% and 
5.0% cases in the observation studies. In 
observation studies, the ultrasound examinations 
were often performed in inadequate gestation, 
and operators were either not properly trained or 
they were not sufficiently motivated to measure 
NT. In one of the studies, for example, where the 
operators were told not to spend more time 
measuring NT that they need to measure CRL, NT 
thickness was successfully measured in only 66% 
(9). In another study, the CRL was less than 33 
mm in 54% of cases and operators were told to 
measure the NT within three minutes; they could 
not do it in 42% of cases (10). These methodo-
logical problems are highlighted in a study performed 
in 47.053 singleton pregnancies examined between 
6 and 16 weeks (11). In 23% of the pregnant 
women, it was not possible to obtain a valid NT 
measurement because it was performed in an 
inadequate gestation, the operators were unable to 
obtain appropriate measures or none of the images 
were of acceptable quality. An example of the 
difference between observation and intervention 
study is represented by the study carried out by 
Crossley et al (12). In this observation study, 17.229 
cases were examined and fetal NT was successfully 
measured in 73% of cases. In the next study, for 
more than 2.000 pregnancies in which the 
examination results were given to women, fetal NT 
was successfully measured in 99.8% of cases. The 
results of our research show that in the total sample, 
5.04% are pathological karyotypes, 50% of which 
are with numerical aberrations, which is consistent 
with the mentioned results from the available 
literature. Positive predictive value shows the 
number of people with positive finding that have the 
disease, in our sample 0.66. The negative predictive 
value shows the number of people with negative test 
finding that do not have the disease, 0.97 in our 
sample. 
False-positive rate was determined by the 
following formula SLP=LP/LP+SN and amounts to 
0.027. 
  Predictive value of NT as an ultrasonographic 
marker for chromosomopathies if used in isolated 
manner is questionable, which is also confirmed 
in the literature. Result of the significant difference 
of NT thickness in the group of pregnant women 
with pathological karyotype was expected (p<0.05), 
which is confirmed by numerous studies in this 
field. Crown-rump length and gestational age are 
not statistically different (p>0.05) in examined 
groups, which indicate the homogeneity of the 
sample that we examined. Sensitivity of screening 
for chromosomal aberrations by measuring the NT 
is 66% and specificity is 97%. Lower sensitivity of 
chromosomal aberrations screening by measuring 
the NT in the general population indicates that NT 
can not be the only screening tool. From the 
point of establishing the absence of chromosomal 
aberrations, it can be said that such screening by 
measuring NT turned out to be highly specific and 
is 97%. 
 
Conclusion 
 
The likelihood of chromosomal aberrations 
screening by measuring the NT is 66% and 
specificity is 97%. Very high negative predictive 
value of 97% gives the practical meaning that 
the test can be rather considered as "true 
negative" than "false positive". The likelihood 
that a patient with a positive finding of nuchal 
translucency will really be sick, that is to have a 
numerical aberration is 0.66. The likelihood that 
a patient with negative finding of nuchal 
translucency will be healthy is 0.97. The false 
positives rate is 0.026. The specificity of nuchal 
translucency measurement as a marker for 
chromosomopathies is 0.97. Very high negative 
predictive value of 97% gives a practical meaning 
that the test can be considered true negative 
rather than a "false positive". 
Normal finding of nuchal translucency can 
be considered as a useful ultrasonographic 
marker in assessing the absence of chromosomo-
pathies. Pathological finding of nuchal translucency 
diameter should be supplemented with other 
prenatal tests before we give a pregnant woman 
an advice to undergo invasive prenatal diagnosis. 
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PREDIKATIVNA VREDNOST FETALNE NUHALNE TRANSLUCENCE U 
SKRININGU  HROMOZOMSKIH ABERACIJA 
 
Dragan Lončar, Miroslav Stojadinović i Slavica Lončar 
 
 
  U traganju za specifičnim ranim ultrazvučnim znacima koji bi mogli ukazivati na 
povećani rizik od naslednih ili stečenih poremećaja fetusa, naučna istraživanja potvrđuju 
izuzetnu vrednost ultrazvučnog nalaza nuhalne translucence (NT). 
Cilj rada bio je da se utvrdi prediktivna vrednost promera fetalne NT u otkrivanju 
hromozomopatija.  
U ispitivanje je uključeno 317 trudnica sa monofetalnim trudnoćama gestacijske 
starosti 11-14 nedelja. Kontrolnu grupu činile su trudnice kod kojih je nakon 
amniocenteze konstatovan uredan rezultat kariotipa ploda. Nismo određivali granicu 
fiziološkog, odnosno patološkog nalaza vrednosti NT, već smo koristili promere NT koje 
smo dobili kod trudnica sa patološkim rezultatom amniocenteze kao potencijalno 
patološke vrednosti.  
Srednja vrednost NT u kontrolnoj grupi iznosila je 1.92±0.39mm, a u grupi sa 
patološkim nalazom kariotipa ploda iznosila je 2.49±0.37mm, što je statistički značajna 
razlika (p<0.05). Srednja vrednost rastojanja teme trtica u kontrolnoj grupi bila je 
64.83±8.23mm, a u grupi sa patološkim kariotipom 60.12±8.48mm, gestacijska starost 
u kontrolnoj gupi bila je 87.40±7.10 dana, a u patološkoj 85.69±3.98 dana, što govori o 
homogenosti ispitivanog uzorka (p>0.05). Verovatnoća da će bolesnik sa negativnim 
nalazom NT biti zdrav je 0.97. Senzitivnost NT kao markera za hromozomopatije 
iznosila je 0.66. Stopa lažno pozitivnih nalaza je 0.027. Specifičnost NT  kao markera za 
hromozomopatije je 0.97. Verovatnoća da će bolesnik sa pozitivnim nalazom NT stvarno 
biti bolestan je 0.66.  
Uredan nalaz NT može se smatrati pouzdanim ultrasonografskim markerom u 
proceni odsustva hromozomopatija. Patološki nalaz, s obzirom na nisku pozitivnu 
prediktivnu vrednost NT mora biti dopunjen i drugim prenatalnim testovima pre nego što 
trudnici damo savet o invazivnoj prenatalnoj dijagnostici. Acta Medica Medianae 
2011;50(1):11-16.  
 
Ključne reči: nuhalna translucenca, ultrasonografija, hromozomopatije, prediktivna 
statistika 